Compare Ascendis Pharma A/S (ASND) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs PepsiCo, Inc. — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while PepsiCo, Inc. trades at $139.56 (market cap $187.51B). The key difference: PepsiCo, Inc. is far larger — about 10.6× Ascendis Pharma A/S's market cap, and PepsiCo, Inc. pays a 4.31% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PEP | |
|---|---|---|
Market Cap | $17.74B | $187.51B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $170.44 |
52-Week Low | $163.32 | $133.81 |
Enterprise Value | $18.11B | $230.01B |
Dividend Yield | — | 4.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PepsiCo (PEP) trades at $137.99, up 0.44% on the day, with a bearish technical signal but strong fundamentals including a 10.78% net income margin and consistent earnings beats. Recent news highlights price cuts on snacks like Doritos to address consumer resistance, while Q1 2026 results are anticipated. The stock shows robust cash flow from operations of $12.09B in 2025 and a high ROE of 51.59%, though debt-to-asset ratios have risen to 45.85%.
Outlook is mixed: analyst consensus targets $159.27 with 33% buy ratings, but technicals suggest near-term pressure. Risks include competitive pricing pressures and execution of North America turnaround. The dividend yield near 4% and earnings growth potential offer value, yet investors should monitor Q1 results for sustainability signs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
